Short-term fasting lowers glucagon levels under euglycemic and hypoglycemic conditions in healthy humans

JCI Insight. 2023 Jun 22;8(12):e169789. doi: 10.1172/jci.insight.169789.

Abstract

Fasting is associated with increased susceptibility to hypoglycemia in people with type 1 diabetes, thereby making it a significant health risk. To date, the relationship between fasting and insulin-induced hypoglycemia has not been well characterized, so our objective was to determine whether insulin-independent factors, such as counterregulatory hormone responses, are adversely impacted by fasting in healthy control individuals. Counterregulatory responses to insulin-induced hypoglycemia were measured in 12 healthy people during 2 metabolic studies. During one study, participants ate breakfast and lunch, after which they underwent a 2-hour bout of insulin-induced hypoglycemia (FED). During the other study, participants remained fasted prior to hypoglycemia (FAST). As expected, hepatic glycogen concentrations were lower in FAST, and associated with diminished peak glucagon levels and reduced endogenous glucose production (EGP) during hypoglycemia. Accompanying lower EGP in FAST was a reduction in peripheral glucose utilization, and a resultant reduction in the amount of exogenous glucose required to maintain glycemia. These data suggest that whereas a fasting-induced lowering of glucose utilization could potentially delay the onset of insulin-induced hypoglycemia, subsequent reductions in glucagon levels and EGP are likely to encumber recovery from it. As a result of this diminished metabolic flexibility in response to fasting, susceptibility to hypoglycemia could be enhanced in patients with type 1 diabetes under similar conditions.

Trial registration: ClinicalTrials.gov NCT04392843.

Keywords: Diabetes; Endocrinology.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Blood Glucose / metabolism
  • Diabetes Mellitus, Type 1* / drug therapy
  • Diabetes Mellitus, Type 1* / metabolism
  • Glucagon
  • Glucose / metabolism
  • Humans
  • Hypoglycemia* / chemically induced
  • Hypoglycemia* / metabolism
  • Hypoglycemic Agents
  • Insulin
  • Intermittent Fasting

Substances

  • Glucagon
  • Blood Glucose
  • Insulin
  • Glucose
  • Hypoglycemic Agents

Associated data

  • ClinicalTrials.gov/NCT04392843